SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo, Inc. Shifts 6 Early Drug Programs to India

February 8, 2011 | 
1 min read
Rediff -- Daiichi Sankyo, Japan's third-largest drug maker, has transferred six of its early drug discovery programmes in inflammatory and infectious diseases from its Japanese research & development (R&D) facilities to India.
Asia
Daiichi Sankyo
MORE ON THIS TOPIC
Contemporary art collage. Motivated, confident team go over light background with abstract object, red arrows. Concept of business development, teamwork, startup, finance, career.
Job Trends
Biopharma cuts at manufacturing plants expected to affect 4,000+
October 29, 2026
 · 
5 min read
 · 
Angela Gabriel
Perspective view of supermarket aisle. Supermarket with colorful shelves of merchandise and front door and supermarket food cart. Cartoon vector illustration
Immunology and inflammation
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
October 23, 2026
 · 
1 min read
 · 
Annalee Armstrong
3d sketch poster trend collage image of hands hold chess figurine knight queen rival china america trade war economic problem.
China
US explores China biotech restrictions, exempts licensing deals
October 23, 2026
 · 
3 min read
Creative trend design 3D collage sketch of loss budget business investor crisis american hand hold china finance trade war national budget.
China
China’s licensing deals soar as US biotechs enjoy a bumper M&A year
October 21, 2026
 · 
3 min read
 · 
Annalee Armstrong